The promise of genomics in drug discovery, which was eagerly
embraced in the mid-1990s, has not yet been fulfilled. However,
the influence of modern biology on drug discovery remains
viable. The promise of genomics and biology should be put in
context with the two central problems of drug discovery: The
search for disease-related targets, and the study of drug-protein
interactions and protein-protein interactions. The first tier of the
biotechnology industry has now become the most productive
segment of the drug industry. It combines a high degree of
innovative spirit with solid pharmaceutical professionalism.
Some biotechnology firms have succeeded in addressing un-
met medical needs in technologically appealing ways. In their
totality, these changes will deeply alter the nature and appear-
ance of the drug industry....

PDF Download